Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cervical Cancer: early-phase trial registry
73 of 151 indexed Cervical Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #76 of 28,707 conditions by registered trial count.
151 US clinical trials · 73 currently recruiting · #76 of 28,707 conditions by registered trial count
Cervical Cancer: 151 US clinical trials tracked, 73 recruiting.
Cervical Cancer is the subject of 151 registered US clinical trials on ClinicalTrials.gov, 73 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 78 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition cervical-cancer
OPEN 73 | RECR 48% | LATE 8 | EARLY 78 | RANK #76 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Chronic Graft Versus Host Disease (48% recruiting · 31 trials)
Cervical Cancer lists 73 open slots (48% of 151 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cervical Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cervical Cancer is recruiting above its size-band peers.
73 of 151 indexed trials (48.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cervical Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 11 of 151 trials (7.3%). 101 distinct sponsors appear on at least one study for this condition label.
-
Typical Cervical Cancer enrolment sits around 100 participants.
Median target enrolment is 100 among the 145 trials that report a genuine target (sentinel values excluded). 72 of those (49.7%) plan for fewer than 100 participants.
-
Cervical Cancer research is mostly interventional.
131 interventional and 20 observational studies make up this index (86.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
151 total, page 3 of 4
Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer
University of Texas Southwestern Medical Center
NCT05021237
A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer
Dana-Farber Cancer Institute
NCT03970083
HPV Self-Sampling in Somali Women (Isbaar Project)
University of Minnesota
NCT05453006
A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women
Dartmouth-Hitchcock Medical Center
NCT00376909
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities
M.D. Anderson Cancer Center
NCT00453661
Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care
Dartmouth-Hitchcock Medical Center
NCT00477646
Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix
Gynecologic Oncology Group
NCT00003078
Laparoscopic Approach to Cervical Cancer
Queensland Centre for Gynaecological Cancer
NCT00614211
Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida
University of Miami
NCT02202109
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Michigan State University
NCT01910350
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Seagen, a wholly owned subsidiary of Pfizer
NCT04697628
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
University of Alabama at Birmingham
NCT00703196
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
NCT04925284
Sexual Health Empowerment for Cervical Health Literacy and Cancer Prevention
Megha Ramaswamy, PhD, MPH
NCT02128659
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Agenus
NCT03104699
Southeast Asian Women's Health Project
Ohio State University
NCT04086771
A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping
Novadaq Technologies ULC, now a part of Stryker
NCT02209532
Reducing Barriers and Sustaining Utilization of a Cervical Cancer Screening Program in Rural Senegal
University of Illinois at Chicago
NCT03540069
Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma
Memorial Sloan Kettering Cancer Center
NCT00595725
Understanding the Value of Community Vital Signs in Primary Care
Virginia Commonwealth University
NCT02512835
Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer
Memorial Sloan Kettering Cancer Center
NCT05255393
Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia
M.D. Anderson Cancer Center
NCT00513123
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)
NCT00303823
Promoting Cervical Cancer Screening for Emergency Department Patients
University of Rochester
NCT03483610
Image-Guided Gynecologic Brachytherapy
Dana-Farber Cancer Institute
NCT01399658
chemQbiosciences:Manual Liquid Based Cytology
University of North Carolina, Chapel Hill
NCT01837303
Extraperitoneal Lymph Node Dissection in Patients With Cervical Cancer
M.D. Anderson Cancer Center
NCT00500435
Interventions to Decrease Financial Toxicity
University of Alabama at Birmingham
NCT05939440
Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study
M.D. Anderson Cancer Center
NCT01706705
Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
University of Oklahoma
NCT03476798
Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer
Radiation Therapy Oncology Group
NCT00012012
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Cancer Institute (NCI)
NCT00924027
e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English
Johns Hopkins University
NCT03726619
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03652077
Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stages I, II, or III Cervical Cancer
University of California, Irvine
NCT00086242
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
Gynecologic Oncology Group
NCT00003377
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
M.D. Anderson Cancer Center
NCT01365156
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
NCT00268918
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Dana-Farber Cancer Institute
NCT00545792
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
Masonic Cancer Center, University of Minnesota
NCT00610740
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Memorial Sloan Kettering Cancer Center
NCT00588276
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
SCRI Development Innovations
NCT00315861
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
University of Wisconsin, Madison
NCT02096783
The Femscope Calm Collect Device
University of Michigan
NCT06861504
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Holy Name Medical Center
NCT03604653
Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix
Eastern Cooperative Oncology Group
NCT00003017
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix
Gynecologic Oncology Group
NCT00087113
EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer
Gynecologic Oncology Group
NCT00049231
Vaginal Changes and Sexual Function in Patients With Cervical Cancer
Gynecologic Oncology Group
NCT00053261
Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer
Gynecologic Oncology Group
NCT00002536
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 30 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cervical Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cervical Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cervical Cancer page
151 registered trials, 73 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 73 Cervical Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Cervical Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cervical Cancer condition card totals 151 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.